5.89
0.30 (5.37%)
| Penutupan Terdahulu | 5.59 |
| Buka | 5.66 |
| Jumlah Dagangan | 364,434 |
| Purata Dagangan (3B) | 827,377 |
| Modal Pasaran | 294,091,040 |
| Harga / Buku (P/B) | 2.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -4.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.08% |
| Nisbah Semasa (MRQ) | 7.75 |
| Aliran Tunai Operasi (OCF TTM) | -101.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.88 M |
| Pulangan Atas Aset (ROA TTM) | -31.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -42.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cybin Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.63 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 207.96% |
| % Dimiliki oleh Institusi | 42.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deep Track Capital, Lp | 30 Sep 2025 | 1,000,000 |
| Acorn Capital Advisors, Llc | 30 Sep 2025 | 734,394 |
| Sphera Funds Management Ltd. | 30 Sep 2025 | 370,376 |
| Advisorshares Investments Llc | 30 Sep 2025 | 116,102 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2025 | Pengumuman | Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights |
| 12 Nov 2025 | Pengumuman | Cybin to Participate in the Jefferies Global Healthcare Conference in London |
| 06 Nov 2025 | Pengumuman | Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 |
| 05 Nov 2025 | Pengumuman | Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference |
| 03 Nov 2025 | Pengumuman | Cybin to Participate at the 2025 Milken Institute Future of Health Summit |
| 28 Oct 2025 | Pengumuman | Cybin Announces $175 Million Registered Direct Offering |
| 23 Sep 2025 | Pengumuman | Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones |
| 11 Sep 2025 | Pengumuman | Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit |
| 08 Sep 2025 | Pengumuman | Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |